Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Z Squared Inc's Business Segments
Z Squared Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Technology
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Technology0%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Technology | $ 0 | - |
Revenue by Product & Service Category - Q1 FY2026
- Advertising Campaigns0%
- Sales10%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Advertising Campaigns | $ 0 | - |
| Sales1 | $ 0 | - |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Z Squared Inc
Coeptis Therapeutics Holdings, Inc., formerly Bull Horn Holdings Corp., is a holding company operating through subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., Coeptis Pharmaceuticals, LLC, SNAP Biosciences, Inc., and GEAR Therapeutics, Inc. The company operates in the biopharmaceutical and technology sectors. Its biopharmaceutical division develops cell therapy platforms targeting cancer, autoimmune, and infectious diseases. The technology division provides AI-powered marketing software and robotic process automation tools. Coeptis' product pipeline includes CD38-GEAR-NK, designed to protect CD38-positive natural killer cells from destruction by anti-CD38 monoclonal antibodies, and a CD38-Diagnostic tool to identify candidates for anti-CD38 therapy. The company holds an exclusive license and asset purchase agreement with Deverra Therapeutics Inc. for a stem cell expansion platform and related Phase 1 clinical trials involving unmodified natural killer cell therapies. Coeptis has acquired 50% ownership interests in two Vy-Gen Bio, Inc. technologies focused on CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. The company is advancing its GEAR-NK and SNAP-CAR platforms and pursuing strategic partnerships to develop these therapies.
As of 2024, the Company operates in two segments: Biotechnology and Technology. The Biotechnology Segment focuses on developing its biotechnology product pipeline and does not generate revenue. It reported total assets of $13,783,575 as of December 31, 2025, and $8,366,785 as of December 31, 2024. This segment had no sales in 2025 and 2024, with operating expenses of $13,540,971 in 2025 and $10,054,488 in 2024, resulting in net losses from operations of $(13,540,971) in 2025 and $(10,054,488) in 2024.
The Technology Segment generates revenue by acquiring technology assets to support and enhance operational capabilities through advanced technologies. It reported total assets of $2,370,346 as of December 31, 2025, and $541,875 as of December 31, 2024. In 2025, the Technology Segment recorded sales of $1,363,045, cost of goods sold of $180,625, operating expenses of $684,947, and a net gain from operations of $497,473. It had no sales or expenses in 2024.
The Company’s segment structure reflects differences in future potential revenue streams, customer base, reporting structure, and management’s organization around future revenue-generating activities.